Anti ROR1 anti CD137 Humabody - Crescendo Biologics
Latest Information Update: 13 Sep 2023
At a glance
- Originator Crescendo Biologics
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant proteins
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 04 Sep 2023 Crescendo Biologics has patent protection for Methods for producing optimised therapeutic molecules from transgenic animals in Europe
- 31 May 2023 Anti ROR1 anti CD137 Humabody - Crescendo Biologics is available for licensing as of 31 May 2023 (Crescendo Biologics pipeline, May 2023)https://www.crescendobiologics.com/partnering-overview/
- 31 May 2023 Early research in Cancer in United Kingdom (Parenteral), prior to May 2023 (Crescendo Biologics pipeline, May 2023)